What Is vTv Therapeutics Inc. (VTVT) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, vTv Therapeutics Inc.'s intrinsic value is estimated at a composite fair value of $44.37. At a current market price of $32.69, 9 of 12 active valuation models identify upside potential, projecting an average implied return of +35.7%. Notably, ML-RIV sees the most upside at +141.5% (fair value: $78.95), while Dynamic NAV is the most conservative at -9.8% ($29.50). The spread between these extremes — +151.3% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About VTVT?
12 of 13 models are currently active for VTVT. Of these, 10 models suggest upside while 2 models suggest overvaluation. The Bayesian DCF estimates VTVT's intrinsic value at $34.82, implying +6.5% upside from the current price. See which stocks rank higher →
How Does VTVT Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, VTVT ranks #88 by Quality of Company score. CirclFi's QOC score of 6.5/10 evaluates 32 fundamental signals. A score of 6.5 indicates above-average quality.
See all Most Undervalued Pharmaceutical Preparations Stocks →
vTv Therapeutics Inc.'s positioning within the Pharmaceutical Preparations segment means that patent cliff exposure plays an outsized role in fundamental analysis. The sector's unique characteristics — including orphan drug designation — shape both the opportunity set and risk profile.
Is VTVT a Value Trap?
CirclFi's Value Trap algorithm assigns VTVT a score of 47/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
12 of 13 models are active for vTv Therapeutics Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, vTv Therapeutics Inc. earns a quality score of 6.5/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency. Our Value Trap detector shows moderate caution signals worth monitoring.
The gap between the most bullish and bearish model spans +151.3% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every VTVT valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across VTVT's 12 active models, average confidence is 34%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad